Joan M Neuner1, Nathan Zokoe2, Emily L McGinley2, Liliana E Pezzin3, Tina W F Yen4, Marilyn M Schapira5, Ann B Nattinger3. 1. Medical College of Wisconsin, Department of Medicine, 9200 W Wisconsin Avenue, Milwaukee, WI 53226, USA; Center for Patient Care and Outcomes Research, 8701 Watertown Plank Road, Suite H3100, Milwaukee, WI 53226, USA. Electronic address: jneuner@mcw.edu. 2. Center for Patient Care and Outcomes Research, 8701 Watertown Plank Road, Suite H3100, Milwaukee, WI 53226, USA. 3. Medical College of Wisconsin, Department of Medicine, 9200 W Wisconsin Avenue, Milwaukee, WI 53226, USA; Center for Patient Care and Outcomes Research, 8701 Watertown Plank Road, Suite H3100, Milwaukee, WI 53226, USA. 4. Medical College of Wisconsin, Department of Surgical Oncology, 9200 W Wisconsin Avenue, Milwaukee, WI 53226, USA; Center for Patient Care and Outcomes Research, 8701 Watertown Plank Road, Suite H3100, Milwaukee, WI 53226, USA. 5. Perelman School of Medicine at the University of Pennsylvania, 295 John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104, USA.
Abstract
BACKGROUND: Growing numbers of older women receive adjuvant breast cancer therapies, but little is known about the long-term effects of current therapies upon health-related quality of life outside of clinical trials. METHODS: A population-based cohort of postmenopausal women with incident breast cancer aged sixty-five and older was identified from Medicare claims from four states and followed over five years. General health-related quality of life (HRQOL) was assessed using the Medical Outcomes Study SF-12 Health Survey, and breast cancer-related HRQOL was assessed using the breast cancer subscale of the functional assessment of cancer therapy (FACT-B BCS). The association of HRQOL with sociodemographic variables, comorbidity, and breast cancer variables (stage, treatments, and treatment sequelae) was examined in longitudinal models. RESULTS: Among the 3083 older breast cancer survivors, general HRQOL as measured by SF-12 mental and physical component scores was similar to norms for non-cancer populations, and remained stable throughout follow-up. Breast cancer treatments, including surgery and radiation, adjuvant hormonal therapy, and cytotoxic chemotherapy were not associated with worsened general health scores. A similar pattern was seen for breast cancer-related HRQOL scores, except that chemotherapy was associated with slightly worse scores. Lymphedema occurred in 17% of the cohort, and was strongly associated with all measures of HRQOL. Reductions in general HRQOL with lymphedema development were larger than those with an age increase of 10 years. CONCLUSIONS: There is little association of breast cancer treatment with HRQOL in older breast cancer patients followed for up to five years, but the development of lymphedema is associated with substantial reductions in HRQOL.
BACKGROUND: Growing numbers of older women receive adjuvant breast cancer therapies, but little is known about the long-term effects of current therapies upon health-related quality of life outside of clinical trials. METHODS: A population-based cohort of postmenopausal women with incident breast cancer aged sixty-five and older was identified from Medicare claims from four states and followed over five years. General health-related quality of life (HRQOL) was assessed using the Medical Outcomes Study SF-12 Health Survey, and breast cancer-related HRQOL was assessed using the breast cancer subscale of the functional assessment of cancer therapy (FACT-B BCS). The association of HRQOL with sociodemographic variables, comorbidity, and breast cancer variables (stage, treatments, and treatment sequelae) was examined in longitudinal models. RESULTS: Among the 3083 older breast cancer survivors, general HRQOL as measured by SF-12 mental and physical component scores was similar to norms for non-cancer populations, and remained stable throughout follow-up. Breast cancer treatments, including surgery and radiation, adjuvant hormonal therapy, and cytotoxic chemotherapy were not associated with worsened general health scores. A similar pattern was seen for breast cancer-related HRQOL scores, except that chemotherapy was associated with slightly worse scores. Lymphedema occurred in 17% of the cohort, and was strongly associated with all measures of HRQOL. Reductions in general HRQOL with lymphedema development were larger than those with an age increase of 10 years. CONCLUSIONS: There is little association of breast cancer treatment with HRQOL in older breast cancerpatients followed for up to five years, but the development of lymphedema is associated with substantial reductions in HRQOL.
Authors: Alfred I Neugut; Grace Clarke Hillyer; Lawrence H Kushi; Lois Lamerato; S David Nathanson; Christine B Ambrosone; Dana H Bovbjerg; Jeanne S Mandelblatt; Carol Magai; Wei-Yann Tsai; Judith S Jacobson; Dawn L Hershman Journal: Breast J Date: 2012-04-05 Impact factor: 2.431
Authors: Susan J Bennet; Neil B Oldridge; George J Eckert; Jennifer L Embree; Sherry Browning; Nan Hou; Melissa Deer; Michael D Murray Journal: Qual Life Res Date: 2002-06 Impact factor: 4.147
Authors: Tina W F Yen; Purushottam W Laud; Liliana E Pezzin; Emily L McGinley; Erica Wozniak; Rodney Sparapani; Ann B Nattinger Journal: Med Care Date: 2018-01 Impact factor: 2.983
Authors: Harveshp D Mogal; Marissa Howard-McNatt; Rebecca Dodson; Nora F Fino; Clancy J Clark Journal: Support Care Cancer Date: 2016-12-16 Impact factor: 3.603
Authors: Ajeet Gajra; Linda McCall; Hyman B Muss; Harvey J Cohen; Aminah Jatoi; Karla V Ballman; Ann H Partridge; Linda Sutton; Barbara A Parker; Gustav Magrinat; Heidi D Klepin; Jacqueline M Lafky; Arti Hurria Journal: J Geriatr Oncol Date: 2018-03-28 Impact factor: 3.599
Authors: Elizabeth A Chrischilles; Danielle Riley; Elena Letuchy; Linda Koehler; Joan Neuner; Cheryl Jernigan; Brian Gryzlak; Neil Segal; Bradley McDowell; Brian Smith; Sonia L Sugg; Jane M Armer; Ingrid M Lizarraga Journal: Breast Cancer Res Treat Date: 2019-03-09 Impact factor: 4.872
Authors: Magdalena Anna Lazarewicz; Dorota Wlodarczyk; Steinar Lundgren; Randi Johansen Reidunsdatter Journal: Qual Life Res Date: 2019-02-07 Impact factor: 4.147
Authors: Jéssica Alonso-Molero; Trinidad Dierssen-Sotos; Ines Gomez-Acebo; Nerea Fernandez de Larrea Baz; Marcela Guevara; Pilar Amiano; Gemma Castaño-Vinyals; Tania Fernandez-Villa; Victor Moreno; Juan Bayo; Ana Molina-Barceloa; María Fernández-Ortíz; Claudia Suarez-Calleja; Rafael Marcos-Gragera; Xavier Castells; Leire Gil-Majuelo; Eva Ardanaz; Beatriz Pérez-Gómez; Manolis Kogevinas; Marina Pollán; Javier Llorca Journal: Int J Environ Res Public Health Date: 2020-11-13 Impact factor: 3.390